February 12, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards completion of an inspection carried out by the U.S. FDA at the Company's Pithampur (Unit-I) facility. The inspection was carried out between February 3, 2020 and February 11, 2020.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For LUPIN LIMITED

[Signature]

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl.: a/a
U.S. FDA completes inspection of Lupin’s Pithampur (Unit-I) facility

Mumbai, February 12, 2020: Pharma major Lupin Limited (Lupin) today announced the completion of an inspection carried out by the United States Food and Drug Administration (U.S. FDA) at its Pithampur (Unit-I) facility. The inspection was carried out between February 3, 2020 and February 11, 2020. The inspection for the Pithampur (Unit-I) facility closed with two 483 observations.

Commenting on the outcome of the inspection, Nilesh Gupta, Managing Director, Lupin said, “We uphold the highest standards of quality and compliance across our manufacturing operations and are committed to consistently produce and distribute products of the highest quality.”

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6% of its revenues on research and development.

Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupinglobal/ |
Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra  
Head – Investor Relations and Corporate Communications  
Email: arvindbothra@lupin.com  
Tel: +91-22 6640 8237

Manjira Sharma  
General Manager – Corporate Communications  
Email: manjirasharma@lupin.com  
Tel: +91-22-6640 2532